Medpace Holdings Management

Management criteria checks 4/4

Medpace Holdings' CEO is August Troendle, appointed in Jul 1992, has a tenure of 32.33 years. total yearly compensation is $1.65M, comprised of 49.5% salary and 50.5% bonuses, including company stock and options. directly owns 17.37% of the company’s shares, worth €1.74B. The average tenure of the management team and the board of directors is 5.8 years and 6.3 years respectively.

Key information

August Troendle

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage	49.5%
CEO tenure	32.3yrs
CEO ownership	17.4%
Management average tenure	5.8yrs
Board average tenure	6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has August Troendle's remuneration changed compared to Medpace Holdings's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	US$366m
Jun 30 2024	n/a	n/a	US$340m
Mar 31 2024	n/a	n/a	US$312m
Dec 31 2023	US$2m	US$814k	US$283m
Sep 30 2023	n/a	n/a	US$273m
Jun 30 2023	n/a	n/a	US$268m
Mar 31 2023	n/a	n/a	US$257m
Dec 31 2022	US$2m	US$770k	US$245m
Sep 30 2022	n/a	n/a	US$227m
Jun 30 2022	n/a	n/a	US$209m
Mar 31 2022	n/a	n/a	US$199m
Dec 31 2021	US$6m	US$697k	US$181m
Sep 30 2021	n/a	n/a	US$182m
Jun 30 2021	n/a	n/a	US$175m
Mar 31 2021	n/a	n/a	US$159m
Dec 31 2020	US$4m	US$608k	US$145m
Sep 30 2020	n/a	n/a	US$124m
Jun 30 2020	n/a	n/a	US$107m
Mar 31 2020	n/a	n/a	US$110m
Dec 31 2019	US$8m	US$504k	US$100m
Sep 30 2019	n/a	n/a	US$93m
Jun 30 2019	n/a	n/a	US$88m
Mar 31 2019	n/a	n/a	US$78m
Dec 31 2018	US$528k	US$420k	US$73m
Sep 30 2018	n/a	n/a	US$61m
Jun 30 2018	n/a	n/a	US$52m
Mar 31 2018	n/a	n/a	US$45m
Dec 31 2017	US$598k	US$419k	US$39m

Compensation vs Market: August's total compensation ($USD1.65M) is below average for companies of similar size in the German market ($USD4.78M).

Compensation vs Earnings: August's compensation has been consistent with company performance over the past year.

CEO

August Troendle (68 yo)

32.3yrs

Tenure

US$1,646,031

Compensation

Dr. August James Troendle, M.D. serves as Chairman of CinRx Pharma, LLC. He has been the Chairman, Chief Executive Officer at Medpace Holdings, Inc. since July 1992 and served as its President since July 1...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
August Troendle	Chairman & CEO	32.3yrs	US$1.65m	17.37% € 1.7b
Jesse Geiger	President	3.3yrs	US$945.08k	0.069% € 6.9m
Kevin Brady	CFO & Treasurer	5.8yrs	US$690.48k	0.019% € 1.9m
Susan Burwig	Executive Vice President of Operations	7.8yrs	US$1.12m	0.21% € 21.0m
Stephen Ewald	Chief Compliance Officer	12.4yrs	US$914.64k	0.043% € 4.3m
Brandon Ebken	Chief Information Officer	3.8yrs	no data	no data
Lauren Morris	Associate Director of Investors Relations	no data	no data	no data
Todd Meyers	Vice President of Business Development & Marketing	no data	no data	no data
John Wynne	Senior Vice President of Commercial Operations & Clinical Pharmacology Unit	no data	no data	no data
Reinilde Heyrman	Chief Medical Officer of Medical Department	1.8yrs	no data	no data
Gina Leisring	Senior Vice President of Clinical Monitoring	no data	no data	no data

5.8yrs

Average Tenure

58yo

Average Age

Experienced Management: 01P's management team is seasoned and experienced (5.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
August Troendle	Chairman & CEO	32.3yrs	US$1.65m	17.37% € 1.7b
Fred Davenport	Lead Independent Director	6.3yrs	US$264.98k	0.0065% € 644.8k
Cornelius McCarthy	Independent Director	6.3yrs	US$217.48k	0.017% € 1.7m
Robert Kraft	Independent Director	8.3yrs	US$227.35k	0.0019% € 190.9k
Brian Carley	Independent Director	8.3yrs	US$234.97k	0.070% € 7.0m
Femida Gwadry-Sridhar	Independent Director	1.8yrs	US$258.37k	0% € 0
Dani Zander	Director	less than a year	no data	no data

6.3yrs

Average Tenure

66yo

Average Age

Experienced Board: 01P's board of directors are considered experienced (6.3 years average tenure).

Medpace Holdings Management

Management criteria checks 4/4

Key information

Recent management updates

Executive Vice President of Operations recently sold €2.8m worth of stock

Chairman & CEO recently sold €3.5m worth of stock

Chairman & CEO recently sold €6.3m worth of stock

Medpace Holdings, Inc., Annual General Meeting, May 17, 2024

Chairman & CEO recently sold €23m worth of stock

Executive Vice President of Operations recently sold €3.5m worth of stock

Recent updates

Investor sentiment improves as stock rises 16%

Third quarter 2024 earnings released: EPS: US$3.11 (vs US$2.30 in 3Q 2023)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Medpace Holdings, Inc. to Report Q3, 2024 Results on Oct 21, 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: US$2.85 (vs US$2.00 in 2Q 2023)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Medpace Holdings, Inc. to Report Q2, 2024 Results on Jul 22, 2024

Executive Vice President of Operations recently sold €2.8m worth of stock

Chairman & CEO recently sold €3.5m worth of stock

Chairman & CEO recently sold €6.3m worth of stock

New minor risk - Share price stability

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$3.33 (vs US$2.35 in 1Q 2023)

Medpace Holdings, Inc., Annual General Meeting, May 17, 2024

Medpace Holdings, Inc. to Report Q1, 2024 Results on Apr 22, 2024

Chairman & CEO recently sold €23m worth of stock

Investor sentiment improves as stock rises 18%

Full year 2023 earnings released: EPS: US$9.21 (vs US$7.57 in FY 2022)

Executive Vice President of Operations recently sold €3.5m worth of stock

Now 21% undervalued

Chairman & CEO recently sold €20m worth of stock

Medpace Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2023 and 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: US$2.30 (vs US$2.13 in 3Q 2022)

Medpace Holdings, Inc. to Report Q3, 2023 Results on Oct 23, 2023

Now 20% undervalued

Second quarter 2023 earnings released: EPS: US$2.00 (vs US$1.52 in 2Q 2022)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2023

Medpace Holdings, Inc. to Report Q2, 2023 Results on Jul 24, 2023

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Growth-Defensive Index

Now 21% undervalued

First quarter 2023 earnings released: EPS: US$2.35 (vs US$1.76 in 1Q 2022)

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: US$7.58 (vs US$5.06 in FY 2021)

Medpace Holdings, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023

Medpace Holdings, Inc. Announces Resignation of Thomas C. King to Board

CFO & Treasurer recently sold €440k worth of stock

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$2.13 (vs US$1.35 in 3Q 2021)

Medpace Holdings, Inc. (NasdaqGS:MEDP) announces an Equity Buyback for $500 million worth of its shares.

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2022 and 2023

Medpace Holdings, Inc. to Report Q3, 2022 Results on Oct 24, 2022

Chairman & CEO recently bought €15m worth of stock

Chairman & CEO recently bought €10m worth of stock

Second quarter 2022 earnings released: EPS: US$1.52 (vs US$1.11 in 2Q 2021)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022

Medpace Holdings, Inc. to Report Q2, 2022 Results on Jul 25, 2022

Insufficient new directors

First quarter 2022 earnings released: EPS: US$1.76 (vs US$1.21 in 1Q 2021)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022

Medpace Holdings, Inc., Annual General Meeting, May 20, 2022

Investor sentiment improved over the past week

Lead Independent Director recently bought €64k worth of stock

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Medpace Holdings, Inc. Provides Consolidated Earnings Guidance for the Year 2022

Now 22% undervalued after recent price drop

Third quarter 2021 earnings released: EPS US$1.36 (vs US$1.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS US$1.11 (vs US$0.68 in 2Q 2020)

First quarter 2021 earnings released: EPS US$1.21 (vs US$0.80 in 1Q 2020)

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2021

Medpace Holdings, Inc. to Report Q1, 2021 Results on Apr 26, 2021

Executive Vice President of Operations recently sold €859k worth of stock

Full year 2020 earnings released: EPS US$4.07 (vs US$2.79 in FY 2019)

Revenue beats expectations

New 90-day high: €121

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index

Medpace Holdings, Inc. to Report Q4, 2020 Results on Feb 15, 2021